Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Recruiting 53Active not recruiting 49Completed 15Terminated 9Not yet recruiting 6Suspended 2

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Pancreatic Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Colorectal Neoplasms 1Carcinoma 1

Interventions

Specimen Handling 57Magnetic Resonance Spectroscopy 39Carboplatin 32Cyclophosphamide 29Gemcitabine 28Bevacizumab 24pembrolizumab 23Cisplatin 23Biopsy 23Paclitaxel 22Standard of Care 21Radiotherapy 21Drug Therapy 21fludarabine 20Injections 20Capecitabine 20venetoclax 19Oxaliplatin 19Nivolumab 18Interviews as Topic 17toripalimab 16Dexamethasone 16Blood Specimen Collection 16Radiosurgery 14tislelizumab 13cemiplimab 13anlotinib 13Azacitidine 13Pemetrexed 12Irinotecan 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Not yet recruiting × Ipilimumab × 90 days × Clear all
NCT07355205 2026-05-22

FLINN

Washington University School of Medicine

Phase 2 Not yet recruiting
26 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07603856 2026-05-22

REVIVE

University of Chicago

Phase 2 Not yet recruiting
39 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07587827 2026-05-14

ODI-2001-01

Centre Georges Francois Leclerc

Phase 1 Not yet recruiting
77 enrolled
Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT07430202 2026-05-06

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Carcinoma, Liver Neoplasms

NCT07511036 2026-04-06

PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma

M.D. Anderson Cancer Center

Phase 2 Not yet recruiting
20 enrolled
Dermatologic

Melanoma

NCT07501117 2026-03-30

Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma

Herlev Hospital

Phase 1 Not yet recruiting
15 enrolled
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡